New Center Aims to Make Gene Therapy as Routine as Surgery

Nearly 400 million people worldwide live with rare diseases, yet fewer than 5% of these conditions have approved treatments. That's about to change thanks to a bold new approach that treats genetic medicine like any other life-saving medical procedure.

The Center for Therapeutic Genetics just launched with a simple but powerful mission: make precision gene therapy scalable and repeatable. Instead of treating each rare disease patient as a one-off miracle, the center's founders believe they can create a standardized system that works again and again.

The numbers make this work urgent. Half of all rare disease patients are children, and 30% of those kids won't survive past their fifth birthday. While individual success stories exist, like Baby KJ Muldoon who received personalized CRISPR therapy, these victories remain exceptions rather than the rule.

"What if treating genetic disease could be as routine as life-saving surgery?" asks Dr. Winston Yan, the center's director and physician-scientist at the Broad Institute. He's joined by leaders from The Jackson Laboratory, Boston Children's Hospital, and the Broad Institute who share this vision.

The center received a major boost with a $34.5 million award to develop precision gene-editing treatments for rare genetic epilepsies. But the real innovation isn't just the technology. It's the approach.

Think of it like surgery. Every operation is customized to the patient, but surgeons follow proven protocols and share best practices. The center wants to do the same with CRISPR, base editing, and prime editing technologies. They're building programmable medicines that can be adapted to each patient's needs while following a reliable framework.

Dr. David Liu, a core member at the Broad Institute, receives messages weekly from desperate parents asking for help. "The honest answer today is usually 'not yet,' often not because the science doesn't exist, but because we don't yet have the infrastructure," he explains. The center exists to close that gap.

The Ripple Effect

What starts with rare diseases won't end there. The systems and methods developed for treating genetic epilepsies or ultra-rare conditions will pave the way for addressing more common diseases. Every breakthrough accelerates the next one.

Dr. Wendy Chung, chief of pediatrics at Boston Children's Hospital, sees families every day for whom a diagnosis is just the beginning of a long journey. "We are at a moment in genomic medicine where, for many rare diseases, the question is no longer whether we can treat them, but whether we will build the systems to do it," says Dr. Cat Lutz of The Jackson Laboratory.

The center plans to share all methods, data, and training openly across institutions. By approaching genetic medicines as a clinical procedure rather than individual products, they're creating a blueprint that any hospital could eventually follow.

For the millions of families waiting for answers, hope is becoming infrastructure.